SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to significant price movement and high trading volume, sparking discussions about a potential short squeeze. The community is actively debating entry points, profit-taking strategies, and whether the stock will continue its upward trajectory, drawing comparisons to other high-flying stocks. Some traders are pointing to the company's low float and recent focus on AI-powered robotics as potential catalysts for continued momentum.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

Radiopharm Theranostics Ltd - ADR

RADX is trending due to positive interim results from its RAD 101 Phase 2b imaging trial, showing promise in brain metastases diagnosis, with a webinar scheduled for further discussion. The community is actively discussing the potential for a short squeeze and significant price movement based on this news and the company's upcoming webinar. Some traders are pointing to the company's cash runway and potential for acquisition, while others express concern about potential dilutions and recent trading volatility.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending amid speculation that the Trump administration may soon reclassify marijuana, potentially as early as Monday, sparking excitement within the cannabis sector. The community is actively discussing the implications of this potential policy change on US-based cannabis companies and debating whether this time the long-awaited catalyst will finally materialize. Some traders are wary of previous false alarms, while others are eagerly anticipating a substantial re-rating of cannabis stocks.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation surrounding potential U.S. cannabis rescheduling following comments from President Trump, fueling community discussions about executive action and its potential impact. Traders are debating the likelihood and timing of any formal announcement, as well as the potential for a short squeeze. Community members are actively discussing the stock's price movement, potential catalysts, and trading strategies.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending due to concerns about slower growth, with community members pointing to recent CFO commentary at a conference and an analyst downgrade as potential drivers for price suppression. Despite this, some are optimistic about PayPal's fundamentals, aggressive buybacks, and strategic moves into areas like banking and stablecoins, viewing the negative sentiment as a contrarian buying opportunity. Community members are discussing the potential for a turnaround and the possibility of a short squeeze.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the stock makes new 2025 highs, with community members discussing its potential to reach $500 amidst debate on the company's valuation and Elon Musk's influence. Speculation around Tesla's autonomous driving advancements and the potential for a SpaceX IPO are also fueling the conversation, alongside concerns about the company's fundamentals.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending as investors digest a significant EV write-down and a strategic shift towards hybrid vehicles, which is being interpreted by some as a pragmatic move to focus on profitability and align with current market demand. The community is actively discussing the implications of this shift, with debates around whether it signals a retreat from EVs or a necessary adjustment in a challenging market landscape. Amidst the EV strategy recalibration, analysts are weighing in, setting price targets and evaluating Ford's potential to capitalize on policy shifts favoring domestic production.

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

ARTV is trending following news of FDA Fast Track designation for its AlloNK therapy in refractory rheumatoid arthritis, which has sparked significant price movement and heavy trading volume. The community is discussing potential price targets, short squeezes, and the company's financial outlook, while analysts have increased price targets. Bullish sentiment is fueled by the therapy's potential in a large autoimmune market.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending amid discussions about its AI strategy and a potential acquisition, sparking mixed community sentiment.  Some believe NOW is well-positioned to benefit from AI, while others express concerns about market share and valuation.  The stock's recent price decline and high trading volume are also driving conversation.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics is trending due to community discussion around a recent offering, with some investors viewing it as a strategic move by someone wanting a large stake. Others express concern about dilution, while some highlight positive Phase 2 data and analyst upgrades, particularly from Morgan Stanley, who raised their price target; Many are looking to MG data and potential buyout catalysts in the coming year.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Detailed Fundamental Analysis - VONG

Below is Validea's ETF fundamental report for Vanguard Russell 1000 Growth ETF (VONG). The report looks at VONG's exposure to the major investing factors including value, quality, momentum and low...

Should Vanguard Russell 1000 Growth ETF (VONG) Be on Your Investing Radar?

Viking Therapeutics has faced a tough start to 2025, with its shares down more than 22% as of Thursday’s close.On Wednesday, the San Diego-based clinical-stage biopharmaceutical company reported a fourth-quarter loss of $0.32 per share, which was wider than the expected $0.27.&nbsp;Viking is still in the development phase and has yet to generate revenue, a common scenario for small- and mid-cap biotech startups.As of Dec. 31, 2024, Viking had $903 million in cash and investments, which it says will help it achieve critical clinical milestones, including completing Phase 3 trials for its subcutaneous version of VK2735, an obesity therapy.In a recent Stocktwits poll, retail traders were asked for their stock price expectations for Viking by the end of 2025.&nbsp;A significant 35%&nbsp;of the poll respondents believe the stock will close below $30, while 32% expect it to rise above $80, a level last seen in late October.&nbsp;Meanwhile, 18% anticipate the stock will end the year between $50 and $80, and 15% see it landing between $30 and $50.<figure class="image"><img style="aspect-ratio:1306/650;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/VKTX_price_prediction_Stocktwits_poll_on_Feb_7_30c9d66fd7.png" alt="VKTX price prediction Stocktwits poll on Feb 7.png" width="1306" height="650"><figcaption>VKTX price prediction Stocktwits poll on Feb 7</figcaption></figure>In 2024, Viking reported positive results from four different clinical trials, including a Phase 2 study for subcutaneous VK2735, a Phase 1 trial of an oral tablet form of VK2735, a Phase 2b study for VK2809 to treat metabolic steatohepatitis (MASH) and fibrosis, and a Phase 1b study of VK0214 for X-linked adrenoleukodystrophy.&nbsp;However, there is growing concern over increased competition in the weight-loss drug market, with Novo Nordisk and Eli Lilly dominating the sector.William Blair and Oppenheimer analysts have speculated that Viking could be an acquisition target for a larger company.&nbsp;This premise gained momentum earlier this week when Novartis CEO Vas Narasimhan revealed that the company is seeking next-generation obesity drug candidates.&nbsp;Shares of Viking spiked on the news, despite Novartis’s own obesity program being in the early stages of development, with no human clinical trials yet.Retail traders on Stocktwits are also bullish on the possibility of a merger or acquisition, especially as Viking’s shares have fallen by over 50% in the past three months.&nbsp;Notably, short interest on Viking has surged from 11.9% in mid-November to over 18% by the end of January.Wall Street’s average price target for Viking is $105.73, representing an upside of more than 230% from current levels.Morgan Stanley analysts, in a note on Thursday, said that after meeting with Viking's management, the company remains confident in securing a commercial manufacturing contract for subcutaneous VK2735, supporting a multibillion-dollar opportunity.The brokerage reiterated its 'Overweight' for the stock and its price target of $105.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Viking Therapeutics Stock Down Over 20% In 2025: Retail Traders Predict Where It Could End The Year

In 2024, Viking reported positive results from four different clinical trials, including a Phase 2 study for subcutaneous VK2735 and a Phase 1 trial of an oral tablet form of VK2735 to treat obesity.

Equity

In 2024, Viking reported positive results from four different clinical trials, including a Phase 2 study for subcutaneous VK2735 and a Phase 1 trial of an oral tablet form of VK2735 to treat obesity.


Current Price	$120.73
Prev Close	$121.30
Open	$122.00
Dividend Yield	N/A
50-Day Moving Average	$121.94
Beta	N/A
Avg. Volume	2.08M
PE Ratio	N/A

52-Week High	$126.83
52-Week Low	$79.40
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

VONG
Vanguard Russell 1000 Growth Index ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VONG News

VONGVanguard Russell 1000 Growth Index ETF